New painkiller with no apparent side effects or addictive qualities near to market

January 25, 2011

(PhysOrg.com) -- A powerful new painkiller, which was developed on the basis of the research conducted at Stony Brook University and with no apparent side effects or addictive qualities, may now be only a year or two from the consumer market.

"This offers a major paradigm shift in the control of pain," declares Dr. Simon Halegoua, Professor of Neurobiology & Behavior at Stony Brook who in the 1990s, teamed up with fellow Stony Brook professors Dr. Gail Mandel and Dr. Paul Brehm to identify a novel sodium ion channel involved in the transmission of pain. They predicted that a drug aimed at blocking this channel, PN1/Nav 1.7, would control pain. PN1 (Peripheral Neuron 1), is uniquely expressed in peripheral nerves such as those involved in pain transduction.

"When a patient is given an opiate like morphine, pain signals are still transmitted from sensory nerves to the central nervous system. Morphine action throughout the brain reduces and alters pain perception, but it also impairs judgement and results in drug dependence," explains Halegoua, also director of the Center for Nervous System Disorders at Stony Brook University. "With drugs targeting the PN1/Nav1.7 sodium ion channel, the pain signals would not be transmitted, even by the sensory nerves. And since the central is taken out of the equation, there would be no and no addictive qualities."

The potential for such drugs is enormous – the reduction or elimination of pain for patients with cancer, arthritis, migraine headaches, muscle pain, pain from burns, and from other debilitating diseases.

He notes that drugs in both oral and topical ointment forms, based on the research he conducted in a basement laboratory at Stony Brook with Mandel, a molecular biologist, and Brehm, an electrophysiologist, are currently in Phase II clinical trials in England and Canada.

The Research Foundation of the State University of New York is the holder of the various patents originating from the work of the Stony Brook researchers. Icagen Inc., now in partnership with Pfizer, holds the exclusive license to these patents and has announced their own drug has now entered Phase I clinical trials in the U.S.

Related Stories

Recommended for you

Scientists find key to regenerating blood vessels

November 23, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The ...

Researchers find infectious prions in Creutzfeldt-Jakob disease patient skin

November 22, 2017
Creutzfeldt-Jakob disease (CJD)—the human equivalent of mad cow disease—is caused by rogue, misfolded protein aggregates termed prions, which are infectious and cause fatal damages in the patient's brain. CJD patients ...

Surprising roles for muscle in tissue regeneration, study finds

November 22, 2017
A team of researchers at Whitehead has illuminated an important role for different subtypes of muscle cells in orchestrating the process of tissue regeneration. In a paper published in the November 22 issue of Nature, they ...

Study reveals new mechanisms of cell death in neurodegenerative disorders

November 22, 2017
Researchers at King's College London have discovered new mechanisms of cell death, which may be involved in debilitating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Cinnamon turns up the heat on fat cells

November 21, 2017
New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice—cinnamon—might be enlisted in the fight against obesity.

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

5 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

that_guy
3 / 5 (2) Jan 25, 2011
Tip of the hat to this guy for good medicinal research.
neiorah
5 / 5 (3) Jan 25, 2011
I wonder what blocking the sodium ion channel will do regarding other purposes they serve.
CarolinaScotsman
5 / 5 (1) Jan 25, 2011
Does the drug block other signals besides pain? If not, how does it discriminate between pain and say normal touch sensation. It it does block other signals, what dangers might that entail?
Caliban
2.7 / 5 (3) Jan 25, 2011
It was always my understanding that pain also served the purpose of stimulating the healing response in damaged areas.
So my question is- will this chemical, by entirely blocking pain impulse from the source to the brain, interfere with the healing process?
If so, then it would appear to only be useful in cases of palliative care for terminal illness.

I'm wondering if maybe there is some information missing here...

neilaconway
5 / 5 (1) Jan 26, 2011
Pain, or at least the reaction to it, serves to protect the body from further harm. Generalized suppression of any messages are certainly going to have unforeseen consequences. The system developed in partnership with some other system within the body; would this lead to an atrophy in the dependent system?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.